Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical relevance of circulating KRAS mutated DNA in plasma from patients with advanced pancreatic cancer.

Molecular oncology - 1 Apr 2016

Tjensvoll Kjersti, Lapin Morten, Buhl Tove, Oltedal Satu, Steen-Ottosen Berry Katrine, Gilje Bjørnar, Søreide Jon Arne, Javle Millind, Nordgård Oddmund, Smaaland Rune

Abstract excerpt

We used KRAS mutations to investigate the clinical relevance of circulating tumor DNA (ctDNA) measurements in patients with advanced pancreatic cancer. Fifty-three blood samples were collected from 14 prospectively recruited patients prior to chemotherapy (gemcitabine or FOLFIRINOX) and subsequently every month during treatment. Samples were processed by density centrifugation and plasma DNA isolation. A...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Disease-Free Survival

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA, Neoplasm

Share to Follow-Up Studies

Share to Pancreatic Neoplasms

Share to Pilot Projects

Share to Proto-Oncogene Proteins p21(ras)

Share to Survival Rate

Source

Open in PubMed Open full text

Identifiers

PMID: 26725968
DOI: 10.1016/j.molonc.2015.11.012
PMCID: PMC5423145

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical relevance of circulating KRAS mutated DNA in plasma from patients with advanced pancreatic cancer.PMID 26725968Read ↗

Mutant KRAS Circulating Tumor DNA Is an Accurate Tool for Pancreatic Cancer Monitoring.Semantic proximity Read ↗

Quantitative monitoring of circulating tumor DNA in patients with advanced pancreatic cancer undergoing chemotherapy.Semantic proximity Read ↗

Evaluation of circulating cell-free KRAS mutational status as a molecular monitoring tool in patients with pancreatic cancer.Semantic proximity Read ↗

Monitoring of circulating tumour DNA in advanced pancreatic ductal adenocarcinoma predicts clinical outcome and reveals disease progression earlier than radiological imaging.Semantic proximity Read ↗

Optimal Value of Mutant KRAS Circulating Tumor DNA for Predicting Prognosis and Monitoring in Patients with Pancreatic Adenocarcinoma: A Prospective Multicenter Cohort Study.Semantic proximity Read ↗

Detection of KRAS Mutations in Circulating Tumor DNA by Digital PCR in Early Stages of Pancreatic Cancer.Semantic proximity Read ↗

Evaluation of circulating tumor DNA as a biomarker in pancreatic cancer with liver metastasisSemantic proximity Read ↗

Longitudinal profiling of circulating tumour DNA for tracking tumour dynamics in pancreatic cancerSemantic proximity Read ↗

Longitudinal profiling of circulating tumour DNA for tracking tumour dynamics in pancreatic cancer.Semantic proximity Read ↗

Prognostic value of circulating tumour DNA in patients undergoing curative resection for pancreatic cancer.Semantic proximity Read ↗

Development of a prediction system for KRAS mutation detection via circulating tumour DNA analysis among patients with unresectable pancreatic cancerSemantic proximity Read ↗

Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.